Eterna Therapeutics Welcomes New Board Member Peter Cicala

Eterna Therapeutics (ERNA) has released an update.

Eterna Therapeutics Inc. has appointed Mr. Peter Cicala to its Board of Directors, where he will serve until the 2024 Annual Meeting of Stockholders. Recognized as an independent director under Nasdaq rules, Cicala will contribute to the Audit, Compensation, and Nominating and Corporate Governance Committees. His appointment was made without any undisclosed arrangements and he has no material interests that require regulatory disclosure. Cicala will receive the company’s standard compensation for non-employee directors and will be covered under the usual indemnification agreement.

For further insights into ERNA stock, check out TipRanks’ Stock Analysis page.